Background: Rotavirus infection and its associated hospitalization of children less than 5 years old in middle- and low-income countries remains a public health challenge. We hypothesized that the Rotarix®potency is affected by non-optimal temperatures which translates into reduced vaccine effectiveness in these settings.
Objective: To assess the effect of non-optimal temperatures on the potency of the Rotarix® vaccine in South Africa.
Methods: Rotarix® vaccine was exposed to temperatures reflecting breaches in the cold chain. Vero cells (ATCC CCL-81)
grown in a 24-well tissue culture plates were infected with Rotarix® vaccine viruses after exposure to non-optimal temperatures and the potency of the vaccine was determined using the plaque assay.
Results: Exposure of the Rotarix® vaccine to seasonal temperatures in KwaZulu-Natal for 6 hours and to extreme temperatures of 40
oC for 72 hours as well as to -20
oC and -80
oC for 12 hours did not affect the potency of the vaccine beyond its expected standard of >7 x 10
5 PFU/ml.
Conclusion: This study revealed that the Rotarix® vaccine remains potent even after exposure to non-optimal temperatures. However, this study only explored the effect of a constant ‘adverse’ temperature on vaccine potency and not the effect of temperature fluctuations.
DOI: https://dx.doi.org/10.4314/ahs.v19i2.22
Cite as: Asowata OE, Ashiru OT, Sturm AW, Moodley P. Stability of a monovalent rotavirus vaccine after exposure to different temperatures observed in KwaZulu-Natal, South Africa. Afri Health Sci.2019;19(2): 1993-1999. https://dx.doi.org/10.4314/ahs.v19i2.22 
